

In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

| 1. Identification of t | he substance or preparation and the company/ undertaking | |
|---|---|--|
| 1.1 <u>Product Identifier</u> | | |
| Product Name: Mast Mycobacteriu | ım Selectatab™ (Kirchner) | |
| Product Code: MS24 | | |
| 1.2 <u>Relevant identified uses of the substance or mixture and uses advised against</u> | | |
| Recommended uses: In vitro diagnostic p | roduct; Laboratory chemical | |
| Uses advised against: No information avai | No information available | |
| 1.3 Details of supplier of the product and safety data sheet | | |
| Manufacturer/supplier: Mast Group Ltd., Mast House, Derby Road, Bootle, Merseyside, UK. L20 IEA Telephone: +44 (0) 151 933 7277 Email: uksales@mastgrp.com Web: www.mastgrp.com Feldstraße 20 23858 Reinfeld Germany Telephone: +49 4533 20 07 34 Email: mast@mast-diagnostica.de Web: www.mast-group.com 1.1 Energency Contact information Web: www.mast-group.com UK contact: Telephone: +44 (0) 151 933 7277 (8am - 5pm GMT Monday to Friday) EU contact: Telephone: +49 4533 20 07 34 (7am - 4pm GMT Monday to Friday) 2. Hazards identification | | |
| 2.1 <u>Classification of the substance or mixture</u> CLP Classification – Regulation (EC) No. 1272/2008 | | |
| CLP Classification – Regulation (EC) No. 1272/2008: Physical hazards: Based on available data, there are no physical hazards | | |
| Heath hazards: This product may cause an allergic skin reaction. | | |
| Environmental hazards | Based on available data, there are no environmental hazards | |
| 2.2 Label elements | | |
| Pictogram | | |
| Signal word | : Danger | |
| Hazard statements | H315 - Causes skin irritation. H319 - Causes serious eye irritation. H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled. H335 - May cause respiratory irritation. H302 - Harmful if swallowed | |
| Precautionary statements | : None | |
| 2.3 <u>Other hazards</u> | | |
| | No information available | |



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

3. Composition/information on ingredients

Composition: A multi-component freeze-dried tablet containing ticarcillin, polymyxin B. Amphotericin B and trimethoprim in an inert carrier.

Hazardous ingredients:

| Component | CAS-No. | EC-No. | Concentration | CLP Classification – 1272/2008/EC | Classification to – 67/548/EEC |
|-------------------------|------------|-----------|---------------|--|--|
| Ticarcillin | 4697-14-7 | - | 26% | Skin Irritant Cat. 2: Eye Irritant Cat. 2: Respiratory Sensitization Cat. 1; Specific target organ toxicity single exposure Cat. 3. H315 - Causes skin irritation. H319 - Causes serious eye irritation. H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled. H335 - May cause respiratory irritation. | Xn, harmful. R36/37/38 Irritating to eyes, respiratory system and skin. R42/43 May cause sensitization by inhalation and by skin contact. |
| Polymyxin B | 1405-20-5 | 215-774-7 | 5% | Acute Toxicity Oral Cat. 4: H302 – harmful if swallowed. | Xn, Harmful. R22, harmful if swallowed. |
| Amphotericin B | 1397-89-3 | 215-742-2 | <5% | Skin Irritant 2; Eye Irritant 2 Specific target organ toxicity – single exposure Cat. 3. H315 - Causes skin irritation. H319 - Causes serious eye irritation. H335 - May cause respiratory irritation. | Xi, irritant. R36/37/38 Irritating to eyes, respiratory system and skin. |
| Trimethoprim lactate | 23256-42-0 | 245-533-1 | <5% | N/A | N/A |

4. First-aid measures

4.1 Description of First Aid measures

General advice: Consult a physician. Show this safety data sheet to the doctor in attendance.

Eye contact: Rinse thoroughly with plenty of water for 10 to 15 minutes, also under the eyelids. Obtain medical attention if irritation persists.

Skin Contact: Wash off skin thoroughly with soap and plenty of water. Obtain medical attention if irritation persists.

Ingestion: Rinse mouth out with plenty of water. Obtain medical attention if symptoms occur.

Inhalation: Move person to fresh air. Obtain medical attention immediately if symptoms occur.

4.2 Most important symptoms and effects, both acute and delayed

No information available.

4.3 Indicate any immediate medical attention and special treatment needed

No information available.

5. Fire fighting measures

5.1 Extinguishing medium

Suitable extinguishing media: Use water spi

media: Use water spray, CO2, foam or dry powder as the extinguisher medium.

Extinguishing media which must not be used for safety reasons:

No information available

5.2 Special hazards arising from the substance or mixture

Combustible material. Thermal decomposition may lead to release of irritating gases and vapours.

5.3 Advice for firefighters

Wear suitable self contained breathing apparatus for fire fighting if necessary.



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

5.4 Additional information

No data available.

6. Accidental release measures

6.1 <u>Personal precautions, protective equipment and emergency procedures</u>

Ensure adequate ventilation. Wear appropriate protective equipment. Avoid dust formation.

6.2 Environmental precautions

Should not be released into the environment.

6.3 <u>Methods and materials for containment and cleaning up</u>

Sweep up or vacuum up spillage in suitable container for disposal. Avoid dust formation.

6.4 **Further information**

No data available.

7. Handling and storage

7.1 Precautions for safe handling

Avoid contact with eyes, skin and clothing. Avoid ingestion and inhalation. Avoid dust formation.

7.2 Conditions for safe storage, including any incompatabilities

Store at 2°C to 8°C. Keep tightly closed in the container provided. Protect from direct sunlight and moisture.

7.3 Specific end use(s)

This product is for laboratory use only and should only be used by suitably trained laboratory personnel.

8. Exposure controls and personal protection

8.1 Control parameters

Components with workspace control parameters: This product has no occupational exposure limits.

8.2 Exposure controls

| Engineering controls: | No engineering protection required. | |
|-------------------------------|--|--|
| Personal protective measures: | Body protection: | Wear standard microbiology laboratory coat. |
| | Eye/face protection: | Safety glasses with side shields conforming to EN 166. |
| | Skin and hand protection: | Handle with suitable gloves conforming to EN 374. Product may be handled with forceps. |
| | Respiratory protection: | If required use a nuisance type particle respirator type P1 EU EN 143. |
| General hygiene measures: | Handle in accordance with good laboratory practice. Wash hands before breaks and at the end of the working day. | |



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

9. Physical and Chemical properties

9.1 Information on basic physical and chemical properties

| Lyophilised tablet. |
|----------------------------|
| White to off-white colour. |
| Odourless. |
| No data available. |
| |

9.2 Other information

No data available.

| 10. Stability and reactivity | | |
|--|--|--|
| 10.1 <u>Reactivity</u> | | |
| | No known on information available. | |
| 10.2 <u>Chemical stability</u> | | |
| | Stable under normal conditions. | |
| 10.3 Possibility of hazardous reactions | | |
| | No data available. | |
| 10.4 Conditions to avoid | | |
| | Hygroscopic. Avoid exposure to sunlight. | |
| 10.5 Incompatible materials | | |
| | None known. | |
| 10.6 <u>Hazardous decomposition products</u> | | |
| | None under normal use conditions. | |
| | | |
| 11. Toxicological information | | |

11.1 Information on toxicological effects

Overall product information: This product does not present an acute toxicity based on known or supplied information.



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

| Acute toxicity: | For ticarcillin - LD ₅₀ Oral - rat - 16,000 mg/kg. Also see RTECS: XM9410000 |
|---|--|
| | For polymyxin B - LD ₅₀ Oral - mouse - 790 mg/kg; LD ₅₀ Intraperitoneal - mouse - 20.5 mg/kg; LD ₅₀ Intravenous - mouse - 5.4 mg/kg. Also see RTECS: TR1150000 |
| | For amphotericin B - LD ₅₀ Oral - rat - >5,000 mg/kg. Also see RTECS: BU2625000 |
| Skin corrosion/irritation: | No data available. |
| Serious eye damage/ eye irritation: | No data available. |
| Respiratory or skin sensitisation: | May cause allergic respiratory reaction. |
| Germ cell mutagenicity: | No data available. |
| Carcinogenicity: | IARC: No component of this product is present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. |
| Reproductive toxicity: | For ticarcillin- Developmental Toxicity - rat - Intravenous Specific Developmental Abnormalities: Musculoskeletal system. Developmental Toxicity - rat - Subcutaneous Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Specific Developmental Abnormalities: Musculoskeletal system. |
| Specific target organ toxicity – single exposure: | No data available. |
| Specific target organ toxicity - repeated exposure: | No data available. |
| Aspiration hazard: | No data available. |
| Potential health effects: | Inhalation May be harmful if inhaled. Causes respiratory tract irritation. Ingestion May be harmful if swallowed. Skin May be harmful if absorbed through skin. Causes skin irritation. Eyes Causes serious eye irritation. |

11.2 <u>Toxicological data for the components</u>

Assess endocrine disrupting properties for human health. This product does not contain any known or suspected endocrine disruptors.

12. Ecological information

12.1 Toxicity

No data available.

12.2 Persistence and degradability

No data available.

12.3 Bioaccumulative potential

No data available.

12.4 Mobility in soil

No data available.

12.5 Results of PBT and vPvB assessment

None known.

12.6 Endocrine disrupting properties: requiring you to give product information on adverse effects on the environment caused by endocrine-disrupting properties

This product does not contain any known or suspected endocrine disruptors.



In accordance with Regulation (EC) No 2020/878 Revision date: 02/11/2022 Version number: 04

12.7 Other adverse effects

No data available

| | 13. Disposal considerations |
|--|--|
| | |
| Disposal considerations: | |
| | Dispose of contaminated waste, e.g. used plates, according to local microbiological rules. |
| | 14. Transport information |
| 14.1 <u>UN Number</u> | |
| ADR/RID: IMDG: IATA: | Not dangerous for shipping |
| 14.2 <u>UN proper shipping name</u> | |
| ADR/RID: IMDG: IATA: | Not dangerous for shipping |
| 14.3 <u>Transport hazard class(es)</u> | |
| ADR/RID: IMDG: IATA: | Not dangerous for shipping |
| 14.4 Packaging group | |
| ADR/RID: IMDG: IATA: | Not dangerous for shipping |
| 14.5 Environmental hazards | |
| ADR/RID: IMDG: IATA: | None known. |
| 14.6 Special precautions for user | |
| | No data available |
| | 15. Regulatory information |

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

No data available.

15.2 Chemical safety assessment

Chemical safety assessment reports are not required for mixtures/IVD products.

| 16. Other information | | |
|--------------------------------|---|--|
| Original origination date: | 31/02/2001 | |
| Reason for change to document: | Updated in accordance with Regulation (EC) No 2020/878 | |
| | The above information is believed to be correct but does not purport to be all inclusive and shall be used as a guide only. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product and is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. Mast Group Ltd. shall not be held liable for any damage resulting from handling or from contact with the above product. See our website at www.mast.grp.com and/or the reverse side of our invoice for additional terms and conditions of sale. | |